Literature DB >> 31619477

Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series.

Jessica Rademacher1,2, Stefanie Konwert3, Jan Fuge2, Sabine Dettmer2,4, Tobias Welte3,2, Felix C Ringshausen3,2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31619477     DOI： 10.1183/13993003.01333-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis.

Authors:  Elizabeth Kudlaty; Gayatri B Patel; Michelle L Prickett; Chen Yeh; Anju T Peters
Journal:  Ann Allergy Asthma Immunol       Date:  2020-12-01       Impact factor: 6.347

Review 2.  Precision medicine in bronchiectasis.

Authors:  Thomas Pembridge; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2021-12

3.  Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study.

Authors:  Xuejie Wang; Carmen Villa; Yadira Dobarganes; Casilda Olveira; Rosa Girón; Marta García-Clemente; Luis Máiz; Oriol Sibila; Rafael Golpe; Rosario Menéndez; Juan Rodríguez-López; Concepción Prados; Miguel Angel Martinez-García; Juan Luis Rodriguez; David de la Rosa; Xavier Duran; Jordi Garcia-Ojalvo; Esther Barreiro
Journal:  Biomedicines       Date:  2022-01-21

Review 4.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.